Home

Medicare Part D 2008: Implications and Challenges for Biotech Products

Fri, 02/22/2008 - 10:27 — Zangani

Listen to Webcast Interview

Zangani Investor Communityâ„¢ interviews Rhonda Greenapple, president & founder of Reimbursement Intelligence. Rhonda discusses how changes to the Medicare benefit impact utilization of biologics, injectables and other high cost products.

  • Impact of increased co payments for use of non generic products on brand utilization
  • Why national plans are using a 4th tier for biologics with significant out of pocket expenses?
  • How Medicare formulary committees look at clinical data that is relevant to their members in deciding tier placement and utilization restrictions?
  • Importance of clinical trial demonstrations, regarding safty and efficiacy in people over 65
  • Best way to maximize access and reimbursement for Medicare populations

    Reimbursement Intelligence is a full-service consulting company that focuses on defining reimbursement strategies and business planning for biocapital companies.

    Learn more about Reimbursement Intelligence by visiting their website at www.reimbursementintelligence.com

    To access the Webcast interview, click here.